Adam Giermasz, M.D., Ph.D.
Philosophy of Care
My Philosophy is to educate my patients and their families so they may participate fully in
decisions about their care. I strive to care in an environment that is open and accepting.
Clinical Interests
Research/Academic Interests
Title
Specialty
Division
Clinic
Center/Program Affiliation
Address/Phone
Dr. Giermasz is a board certified hematologist who specializes in adult hemophilia.
Dr. Giermasz's research interests include: hemophilia, bleeding disorders and thrombosis.
Assistant Professor
Internal Medicine, Hematology Oncology, Adult Hemophilia
Hematology and Oncology
Hematology/Oncology Clinic
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center, Hematology/Oncology Clinic, 4501 X Street 2nd Floor
Sacramento, CA 95817
Phone: 916-734-5959
Additional Phone
Phone: 916-734-3771
Clinic Fax: 916-703-5265
Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Languages
Education
Polish
M.D., Medical University of Warsaw, Warsaw Poland 1998
Ph.D., Molecular Medicine, Medical University of Warsaw, Warsaw Poland 2002
III Secondary School - Lyceum, Warsaw Poland 1992
Internships
University of Pittsburgh Medical Center, Pittsburgh PA 2005-2006
Residency
Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh PA 2006-2008
Fellowships
Board Certifications
Hematology Oncology, UC San Francisco Medical Center, San Francisco CA 2008-2011
American Board of Internal Medicine, 2008
American Board of Internal Medicine, Hematology, 2012
Adam Giermasz, M.D., Ph.D.
Professional Memberships
American Society of Hematology (ASH)
International Society on Thrombosis and Haemostasis
Select Recent Publications
Kono M, Nakamura Y, Suda T, Uchijima M, Tsujimura K, Nagata T, Giermasz A, Kalinski P,
Nakamura H, Chida K. Enhancement of protective immunity against intracellular bacteria using
type-1 polarized dendritic cell (DC) vaccine. Vaccine. 2012 Mar 30;30(16):2633-9.
Giermasz A, Urban JA, Nakamura Y, Watchmaker P, Cumberland RL, Gooding W, Kalinski P.
Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as
cancer vaccines. Cancer Immunol Immunother. 2009 Aug;58(8):1329-36.
Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K,
Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ,
Okada H, Hendricks RL, Kalinski P. Helper function of memory CD8+ T cells: heterologous CD8+
T cells support the induction of therapeutic cancer immunity. Cancer Res. 2007 Oct 15;67(20):
10012-8.
Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB. Helper roles of
NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer
vaccines. Immunol Res. 2006;36(1-3):137-46.
Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB. Helper role
of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol. 2005; 42
(4): 535-9.
Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT,
Herberman RB. Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol
Ther. 2005; 5(10):1303-15.
Adam Giermasz, M.D., Ph.D.
Maiiliard RB, Son Y-I, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P.
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the
induction of NK cell helper function. J Immunol. 2003; 171(5): 2366-73.
O’Connell PJ, Son Y-I, Giermasz A, Wang Z, Logar AJ, Thomson A, Kalinski P. Type-1 polarized - dependent deifferences offset -related dendritic cell heterogeneity. Eur J Immunol 2003; 33(7):
2007-13.
Stoklosa T, Golab J, Wojcik C, Wlodarski P. Jalili A, Januszko A, Giermasz A, Wilczynski GM,
Pleban E, Marczak M, Wilk S, Jakobisiak M. Increased local vascular endothelial growth factor
expression associated with antitumor activity of proteasome inhibitor. Apoptosis 2004; 9: 193-204.
© 2016 UC Regents